Clinical trial • Phase I • Respiratory
AMG 691 for Asthma
Phase I trial of AMG 691 for Asthma. Randomised, placebo (dose/schedule not specified)-controlled. 33 participants.
Overview
- Trial Therapeutic Area
- Respiratory
- Trial Disease
- Asthma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 04-03-2025
- First CTIS Authorization Date
- 27-05-2025
Trial design
Randomised, placebo (dose/schedule not specified)-controlled Phase I trial across 1 site in Belgium.
- Randomised
- Yes
- Comparator
- Placebo (dose/schedule not specified)
- Target Sample Size
- 33
Recruitment
- Planned Sample Size
- 33
- Recruitment Window Months
- 19
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 3
Belgium
- Earliest CTIS Part Ii Submission Date
- 07-04-2025
- Latest Decision Or Authorization Date
- 18-03-2026
- Processing Time Days
- 345
- Number Of Sites
- 1
- Number Of Participants
- 3
Sites
- Site Name
- Emmaues
- Department Name
- Phase 1 Unit
- Principal Investigator Name
- Muriel Lins
- Principal Investigator Email
- Muriel.Lins@Emmaus.be
- Contact Person Name
- Muriel Lins
- Contact Person Email
- Muriel.Lins@Emmaus.be
Sponsor
Primary sponsor
- Full Name
- Amgen Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- AMG 691
Related trials
Other published trials that may interest you.